Smith Salley Wealth Management Has $6.89 Million Stake in Johnson & Johnson (NYSE:JNJ)

Smith Salley Wealth Management decreased its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 26.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,554 shares of the company’s stock after selling 15,425 shares during the quarter. Smith Salley Wealth Management’s holdings in Johnson & Johnson were worth $6,890,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Christopher J. Hasenberg Inc acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at about $31,000. Keener Financial Planning LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at about $40,000. WFA Asset Management Corp increased its position in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $45,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Morgan Stanley decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. The Goldman Sachs Group started coverage on Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price on the stock. upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Finally, Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Check Out Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $149.41 on Thursday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The business’s 50 day simple moving average is $147.93 and its 200 day simple moving average is $153.56. The company has a market cap of $359.58 billion, a price-to-earnings ratio of 9.31, a PEG ratio of 2.42 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.68 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 10.62 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.32%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.